JP2019531745A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019531745A5 JP2019531745A5 JP2019520801A JP2019520801A JP2019531745A5 JP 2019531745 A5 JP2019531745 A5 JP 2019531745A5 JP 2019520801 A JP2019520801 A JP 2019520801A JP 2019520801 A JP2019520801 A JP 2019520801A JP 2019531745 A5 JP2019531745 A5 JP 2019531745A5
- Authority
- JP
- Japan
- Prior art keywords
- cmv
- mir
- vector
- nucleic acid
- acid sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241000701022 Cytomegalovirus Species 0.000 claims 34
- 239000013598 vector Substances 0.000 claims 30
- 239000000427 antigen Substances 0.000 claims 19
- 102000036639 antigens Human genes 0.000 claims 17
- 108091007433 antigens Proteins 0.000 claims 16
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 12
- 150000007523 nucleic acids Chemical group 0.000 claims 12
- 108091008874 T cell receptors Proteins 0.000 claims 8
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims 8
- 210000001744 T-lymphocyte Anatomy 0.000 claims 8
- 108090000623 proteins and genes Proteins 0.000 claims 6
- 108700011259 MicroRNAs Proteins 0.000 claims 5
- 210000004027 cell Anatomy 0.000 claims 5
- 239000002679 microRNA Substances 0.000 claims 5
- 238000000034 method Methods 0.000 claims 4
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 108091023084 miR-126 stem-loop Proteins 0.000 claims 3
- 108091065272 miR-126-1 stem-loop Proteins 0.000 claims 3
- 108091081187 miR-126-2 stem-loop Proteins 0.000 claims 3
- 108091030790 miR-126-3 stem-loop Proteins 0.000 claims 3
- 108091092317 miR-126-4 stem-loop Proteins 0.000 claims 3
- 230000001717 pathogenic effect Effects 0.000 claims 3
- 108090000765 processed proteins & peptides Proteins 0.000 claims 3
- 102000004169 proteins and genes Human genes 0.000 claims 3
- 241000701024 Human betaherpesvirus 5 Species 0.000 claims 2
- 208000006265 Renal cell carcinoma Diseases 0.000 claims 2
- 230000005867 T cell response Effects 0.000 claims 2
- 101150088910 UL82 gene Proteins 0.000 claims 2
- 101150085955 US11 gene Proteins 0.000 claims 2
- 210000003038 endothelium Anatomy 0.000 claims 2
- 230000028993 immune response Effects 0.000 claims 2
- -1 miR-130a Proteins 0.000 claims 2
- 108091079658 miR-142-1 stem-loop Proteins 0.000 claims 2
- 108091071830 miR-142-2 stem-loop Proteins 0.000 claims 2
- 244000052769 pathogen Species 0.000 claims 2
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 1
- 108010083359 Antigen Receptors Proteins 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 108091008875 B cell receptors Proteins 0.000 claims 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 241000282693 Cercopithecidae Species 0.000 claims 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000021309 Germ cell tumor Diseases 0.000 claims 1
- 241000711549 Hepacivirus C Species 0.000 claims 1
- 241000700721 Hepatitis B virus Species 0.000 claims 1
- 241000700588 Human alphaherpesvirus 1 Species 0.000 claims 1
- 241000701074 Human alphaherpesvirus 2 Species 0.000 claims 1
- 241000725303 Human immunodeficiency virus Species 0.000 claims 1
- 206010061598 Immunodeficiency Diseases 0.000 claims 1
- 208000029462 Immunodeficiency disease Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims 1
- 241000282567 Macaca fascicularis Species 0.000 claims 1
- 241000282560 Macaca mulatta Species 0.000 claims 1
- 108091028080 MiR-132 Proteins 0.000 claims 1
- 108091033773 MiR-155 Proteins 0.000 claims 1
- 108091036422 MiR-296 Proteins 0.000 claims 1
- 108091028049 Mir-221 microRNA Proteins 0.000 claims 1
- 108091062140 Mir-223 Proteins 0.000 claims 1
- 208000034578 Multiple myelomas Diseases 0.000 claims 1
- 241000187479 Mycobacterium tuberculosis Species 0.000 claims 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 1
- 208000034176 Neoplasms, Germ Cell and Embryonal Diseases 0.000 claims 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 241001631646 Papillomaviridae Species 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 101150016730 UL79 gene Proteins 0.000 claims 1
- 241000700605 Viruses Species 0.000 claims 1
- 210000002798 bone marrow cell Anatomy 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 230000002708 enhancing effect Effects 0.000 claims 1
- 239000013604 expression vector Substances 0.000 claims 1
- 208000026278 immune system disease Diseases 0.000 claims 1
- 230000007813 immunodeficiency Effects 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 201000004792 malaria Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 108091064282 miR-125 stem-loop Proteins 0.000 claims 1
- 108091037066 miR-125-1 stem-loop Proteins 0.000 claims 1
- 108091062107 miR-125-2 stem-loop Proteins 0.000 claims 1
- 108091079767 miR-125-3 stem-loop Proteins 0.000 claims 1
- 108091032320 miR-146 stem-loop Proteins 0.000 claims 1
- 108091024530 miR-146a stem-loop Proteins 0.000 claims 1
- 108091062762 miR-21 stem-loop Proteins 0.000 claims 1
- 108091041631 miR-21-1 stem-loop Proteins 0.000 claims 1
- 108091044442 miR-21-2 stem-loop Proteins 0.000 claims 1
- 108091048308 miR-210 stem-loop Proteins 0.000 claims 1
- 108091061917 miR-221 stem-loop Proteins 0.000 claims 1
- 108091063489 miR-221-1 stem-loop Proteins 0.000 claims 1
- 108091055391 miR-221-2 stem-loop Proteins 0.000 claims 1
- 108091031076 miR-221-3 stem-loop Proteins 0.000 claims 1
- 108091029997 miR-328 stem-loop Proteins 0.000 claims 1
- 108091027983 miR-378-1 stem-loop Proteins 0.000 claims 1
- 108091089716 miR-378-2 stem-loop Proteins 0.000 claims 1
- 108091050734 miR-652 stem-loop Proteins 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 244000045947 parasite Species 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 210000001519 tissue Anatomy 0.000 claims 1
- 238000001890 transfection Methods 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022169043A JP7478794B2 (ja) | 2016-10-18 | 2022-10-21 | 主要組織適合遺伝子複合体ｅ分子によって拘束されるｔ細胞を誘発するサイトメガロウイルスベクター及びｈｃｍｖベクターを含む組成物 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662409840P | 2016-10-18 | 2016-10-18 | |
| US62/409,840 | 2016-10-18 | ||
| PCT/US2017/057106 WO2018075591A1 (en) | 2016-10-18 | 2017-10-18 | Cytomegalovirus vectors eliciting t cells restricted by major histocompatibility complex e molecules |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022169043A Division JP7478794B2 (ja) | 2016-10-18 | 2022-10-21 | 主要組織適合遺伝子複合体ｅ分子によって拘束されるｔ細胞を誘発するサイトメガロウイルスベクター及びｈｃｍｖベクターを含む組成物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019531745A JP2019531745A (ja) | 2019-11-07 |
| JP2019531745A5 true JP2019531745A5 (OSRAM) | 2020-11-26 |
Family
ID=62018862
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019520801A Pending JP2019531745A (ja) | 2016-10-18 | 2017-10-18 | 主要組織適合遺伝子複合体ｅ分子によって拘束されるｔ細胞を誘発するサイトメガロウイルスベクター |
| JP2022169043A Active JP7478794B2 (ja) | 2016-10-18 | 2022-10-21 | 主要組織適合遺伝子複合体ｅ分子によって拘束されるｔ細胞を誘発するサイトメガロウイルスベクター及びｈｃｍｖベクターを含む組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022169043A Active JP7478794B2 (ja) | 2016-10-18 | 2022-10-21 | 主要組織適合遺伝子複合体ｅ分子によって拘束されるｔ細胞を誘発するサイトメガロウイルスベクター及びｈｃｍｖベクターを含む組成物 |
Country Status (22)
| Country | Link |
|---|---|
| US (2) | US10532099B2 (OSRAM) |
| EP (1) | EP3529363B1 (OSRAM) |
| JP (2) | JP2019531745A (OSRAM) |
| KR (1) | KR102604486B1 (OSRAM) |
| CN (1) | CN110036112B (OSRAM) |
| AU (1) | AU2017346788A1 (OSRAM) |
| BR (1) | BR112019007982A2 (OSRAM) |
| CA (1) | CA3040303A1 (OSRAM) |
| CL (1) | CL2019001054A1 (OSRAM) |
| CO (1) | CO2019004102A2 (OSRAM) |
| CR (1) | CR20190205A (OSRAM) |
| DO (1) | DOP2019000086A (OSRAM) |
| EA (1) | EA201990937A1 (OSRAM) |
| EC (1) | ECSP19031754A (OSRAM) |
| IL (1) | IL266011B2 (OSRAM) |
| MA (1) | MA46588A (OSRAM) |
| MX (1) | MX2019004518A (OSRAM) |
| PE (1) | PE20190840A1 (OSRAM) |
| SG (1) | SG11201903340TA (OSRAM) |
| TN (1) | TN2019000124A1 (OSRAM) |
| UA (1) | UA126860C2 (OSRAM) |
| WO (1) | WO2018075591A1 (OSRAM) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2772265T3 (en) | 2010-05-14 | 2018-04-30 | Univ Oregon Health & Science | Recombinant HCMV and RHCMV vectors and uses thereof |
| ES2667425T3 (es) | 2011-06-10 | 2018-05-10 | Oregon Health & Science University | Glucoproteínas y vectores recombinantes de CMV |
| EP2964769B1 (en) | 2013-03-05 | 2018-08-22 | Oregon Health & Science University | Cytomegalovirus vectors enabling control of t cell targeting |
| KR102205348B1 (ko) | 2014-07-16 | 2021-01-20 | 오레곤 헬스 앤드 사이언스 유니버시티 | 외인성 항원을 포함하는 인간 시토메갈로바이러스 |
| MX2017010027A (es) | 2015-02-10 | 2018-08-15 | Univ Oregon Health & Science | Métodos y composiciones útiles en la generación de respuestas de células t cd8+ no canónicas. |
| CN116926128A (zh) | 2015-11-20 | 2023-10-24 | 俄勒冈健康与科学大学 | 包含微小rna识别元件的cmv载体 |
| SG11201903340TA (en) | 2016-10-18 | 2019-05-30 | Univ Oregon Health & Science | Cytomegalovirus vectors eliciting t cells restricted by major histocompatibility complex e molecules |
| US10632186B1 (en) | 2019-03-21 | 2020-04-28 | 21C Bio | Vaccine to pathogenic immune activation cells during infections |
| US11077185B2 (en) | 2019-03-21 | 2021-08-03 | 21C Bio | Vaccine to pathogenic immune activation cells during infections |
| EP3941517A1 (en) | 2019-03-21 | 2022-01-26 | 21C Bio | Vaccine to pathogenic immune activation cells during infections |
| WO2020247859A2 (en) * | 2019-06-07 | 2020-12-10 | Oregon Health & Science University | Tumor-associated antigen-specific t cell responses |
| CN113950334B (zh) * | 2019-06-07 | 2025-01-28 | 俄勒冈健康与科学大学 | 乙型肝炎病毒特异性t细胞应答 |
| CR20220093A (es) * | 2019-08-20 | 2022-06-15 | Univ Oregon Health & Science | Modulación de las respuestas de células t por ul18 del citomegalovirus humano |
| EP4021923A1 (en) * | 2019-08-29 | 2022-07-06 | VIR Biotechnology, Inc. | Hepatitis b virus vaccines |
| CN114828877A (zh) * | 2019-12-16 | 2022-07-29 | 俄勒冈健康与科学大学 | 多特异性t细胞受体 |
| US20240384296A1 (en) | 2021-08-31 | 2024-11-21 | Vir Biotechnology, Inc. | Recombinant hcmv vectors and uses thereof |
| AU2022339918A1 (en) | 2021-08-31 | 2024-02-08 | Vir Biotechnology, Inc. | Tuberculosis vaccines |
| CN120676955A (zh) | 2022-12-09 | 2025-09-19 | Dys免疫治疗公司 | 产生抗hiv特异性中和抗体和/或抗hiv细胞毒性t细胞的复合aids疫苗 |
Family Cites Families (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5168062A (en) | 1985-01-30 | 1992-12-01 | University Of Iowa Research Foundation | Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence |
| EP0319570B1 (en) | 1987-06-26 | 1995-02-22 | Syntro Corporation | Recombinant human cytomegalovirus containing foreign gene and use thereof |
| US5273876A (en) | 1987-06-26 | 1993-12-28 | Syntro Corporation | Recombinant human cytomegalovirus containing foreign gene |
| EP0521427A1 (en) | 1991-07-05 | 1993-01-07 | American Cyanamid Company | Method for identifying non-essential genes of the human cytomegalovirus genome and for screening for inhibitors of human cytomegalovirus |
| AU7192394A (en) | 1993-07-19 | 1995-02-20 | Cantab Pharmaceuticals Research Limited | Production method for preparation of disabled viruses |
| DE69535125T2 (de) | 1994-04-29 | 2007-08-30 | Pharmacia & Upjohn Co. Llc, Kalamazoo | Impfstoff gegen felines immunodefizienz-virus |
| US5846806A (en) | 1994-07-29 | 1998-12-08 | American Cyanamid Company | Identification of a human cytomegalovirus gene region involved in down-regulation of MHC class I heavy chain expression |
| AU711121B2 (en) | 1995-02-21 | 1999-10-07 | Cantab Pharmaceuticals Research Limited | Viral preparations, vectors, immunogens, and vaccines |
| AU712415B2 (en) | 1995-04-04 | 1999-11-04 | Cell Genesys, Inc. | Transplantation of genetically modified cells having low levels of class I MHC proteins on the cell surface |
| EP0966301B1 (en) | 1996-07-31 | 2005-02-09 | Ortho-McNeil Pharmaceutical, Inc. | Identification of human cytomegalovirus genes involved in down-regulation of mhc class i heavy chain expression |
| US20030138454A1 (en) | 1997-06-09 | 2003-07-24 | Oxxon Pharmaccines, Ltd. | Vaccination method |
| DE19733364A1 (de) | 1997-08-01 | 1999-02-04 | Koszinowski Ulrich H Prof | Verfahren zur Klonierung eines großen Virusgenoms |
| AU3910097A (en) | 1997-08-05 | 1999-03-01 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | Live recombinant vaccine comprising inefficiently or non-replicating vir us |
| US7204990B1 (en) | 2000-11-28 | 2007-04-17 | Medimmune Vaccines, Inc. | Attenuation of cytomegalovirus virulence |
| AU2002242085A1 (en) | 2001-02-02 | 2002-08-19 | Chemocentryx, Inc. | Methods and compositions useful for stimulating an immune response |
| WO2002066629A2 (en) | 2001-02-21 | 2002-08-29 | Gabriele Hahn | Recombinant vector containing infectious human cytomegalovirus genome with preserved wild-type characteristics of clinical isolates |
| GB0122232D0 (en) | 2001-09-14 | 2001-11-07 | Medical Res Council | Gene expression |
| IL160809A0 (en) | 2001-09-20 | 2004-08-31 | Glaxo Group Ltd | HIV-gag CODON-OPTIMISED DNA VACCINES |
| US20030118568A1 (en) | 2001-12-18 | 2003-06-26 | Board Of Trustees Of The University Of Arkansas | Viral stealth technology to prevent T cell-mediated rejection of xenografts |
| JP2005523942A (ja) | 2002-04-30 | 2005-08-11 | アヴィオル セラピューティクス インコーポレイテッド | 免疫療法のためのアデノウイルスベクター |
| DE10232322A1 (de) | 2002-07-16 | 2004-07-29 | Hahn, Gabriele, Dr. | Viral kodierte CxC determinieren den Gewebetropismus von HCMV |
| WO2005012545A2 (en) | 2003-07-25 | 2005-02-10 | The Regents Of The University Of California | Cytomegalovirus gene function and methods for developing antivirals, anti-cmv vaccines, and cmv-based vectors |
| EP2497831B1 (en) | 2004-05-25 | 2014-07-16 | Oregon Health and Science University | TB vaccination using HCMV-based vaccine vectors |
| EP1602676A1 (en) | 2004-06-01 | 2005-12-07 | SOLVAY (Société Anonyme) | Catalytic compositions |
| US20080044384A1 (en) | 2004-06-25 | 2008-02-21 | Medlmmune Vaccines, Inc. | Recombinant Human Cytomegalovirus And Vaccines Comprising Heterologous Antigens |
| WO2006125983A1 (en) | 2005-05-23 | 2006-11-30 | Oxxon Therapeutics Ltd | Compositions for inducing an immune response against hepatitis b |
| US8765146B2 (en) | 2005-08-31 | 2014-07-01 | Genvec, Inc. | Adenoviral vector-based malaria vaccines |
| US20100142823A1 (en) | 2007-03-07 | 2010-06-10 | Ze Wang | 2d partially parallel imaging with k-space surrounding neighbors based data reconstruction |
| EP2167130A2 (en) | 2007-07-06 | 2010-03-31 | Trubion Pharmaceuticals, Inc. | Binding peptides having a c-terminally disposed specific binding domain |
| PE20091434A1 (es) | 2007-10-30 | 2009-10-17 | Genentech Inc | Purificacion de anticuerpos por cromatografia de intercambio cationico |
| JP2012519484A (ja) | 2009-03-06 | 2012-08-30 | マウント・シナイ・スクール・オヴ・メディシン | マイクロｒｎａ応答要素を含む弱毒化生インフルエンザウイルスワクチン |
| AU2010243276B2 (en) | 2009-04-30 | 2016-09-15 | Fondazione Telethon Ets | Gene vector |
| PH12012501308A1 (en) | 2009-12-23 | 2013-01-21 | 4 Antibody Ag | Binding members for human cytomegalovirus |
| CN102844663B (zh) | 2010-01-27 | 2016-01-06 | 俄勒冈健康科学大学 | 基于巨细胞病毒的免疫原性制剂 |
| EP3187585A1 (en) | 2010-03-25 | 2017-07-05 | Oregon Health&Science University | Cmv glycoproteins and recombinant vectors |
| SG185121A1 (en) | 2010-05-05 | 2012-11-29 | Christian Thirion | Vaccine against beta-herpesvirus infection and use thereof |
| DK2772265T3 (en) * | 2010-05-14 | 2018-04-30 | Univ Oregon Health & Science | Recombinant HCMV and RHCMV vectors and uses thereof |
| ES2667425T3 (es) | 2011-06-10 | 2018-05-10 | Oregon Health & Science University | Glucoproteínas y vectores recombinantes de CMV |
| WO2013040320A1 (en) | 2011-09-16 | 2013-03-21 | Oregon Health & Science University | Methods and kits used in identifying microrna targets |
| US20130156808A1 (en) | 2011-11-22 | 2013-06-20 | Stipan Jonjic | Vaccine comprising beta-herpesvirus |
| EP2929034A4 (en) | 2012-12-04 | 2016-06-22 | Merck Sharp & Dohme | VIRUS VECTORS WITH CONDITIONAL REPLICATION |
| EP2964769B1 (en) | 2013-03-05 | 2018-08-22 | Oregon Health & Science University | Cytomegalovirus vectors enabling control of t cell targeting |
| KR102205348B1 (ko) | 2014-07-16 | 2021-01-20 | 오레곤 헬스 앤드 사이언스 유니버시티 | 외인성 항원을 포함하는 인간 시토메갈로바이러스 |
| EP3048114A1 (en) | 2015-01-22 | 2016-07-27 | Novartis AG | Cytomegalovirus antigens and uses thereof |
| MX2017010027A (es) | 2015-02-10 | 2018-08-15 | Univ Oregon Health & Science | Métodos y composiciones útiles en la generación de respuestas de células t cd8+ no canónicas. |
| CN116926128A (zh) | 2015-11-20 | 2023-10-24 | 俄勒冈健康与科学大学 | 包含微小rna识别元件的cmv载体 |
| US11091775B2 (en) * | 2016-06-22 | 2021-08-17 | Oregon Health And Science University | Recombinant cytomegalovirus vectors as vaccines for tuberculosis |
| EP3475446A1 (en) | 2016-06-27 | 2019-05-01 | Juno Therapeutics, Inc. | Method of identifying peptide epitopes, molecules that bind such epitopes and related uses |
| SG11201903340TA (en) | 2016-10-18 | 2019-05-30 | Univ Oregon Health & Science | Cytomegalovirus vectors eliciting t cells restricted by major histocompatibility complex e molecules |
-
2017
- 2017-10-18 SG SG11201903340TA patent/SG11201903340TA/en unknown
- 2017-10-18 JP JP2019520801A patent/JP2019531745A/ja active Pending
- 2017-10-18 CR CR20190205A patent/CR20190205A/es unknown
- 2017-10-18 BR BR112019007982A patent/BR112019007982A2/pt not_active Application Discontinuation
- 2017-10-18 US US15/786,847 patent/US10532099B2/en active Active
- 2017-10-18 MA MA046588A patent/MA46588A/fr unknown
- 2017-10-18 PE PE2019000824A patent/PE20190840A1/es unknown
- 2017-10-18 TN TNP/2019/000124A patent/TN2019000124A1/en unknown
- 2017-10-18 AU AU2017346788A patent/AU2017346788A1/en not_active Abandoned
- 2017-10-18 CA CA3040303A patent/CA3040303A1/en active Pending
- 2017-10-18 CN CN201780064422.7A patent/CN110036112B/zh active Active
- 2017-10-18 IL IL266011A patent/IL266011B2/en unknown
- 2017-10-18 UA UAA201904893A patent/UA126860C2/uk unknown
- 2017-10-18 KR KR1020197013148A patent/KR102604486B1/ko active Active
- 2017-10-18 MX MX2019004518A patent/MX2019004518A/es unknown
- 2017-10-18 EP EP17862978.8A patent/EP3529363B1/en active Active
- 2017-10-18 WO PCT/US2017/057106 patent/WO2018075591A1/en not_active Ceased
- 2017-10-18 EA EA201990937A patent/EA201990937A1/ru unknown
-
2019
- 2019-04-08 DO DO2019000086A patent/DOP2019000086A/es unknown
- 2019-04-17 CL CL2019001054A patent/CL2019001054A1/es unknown
- 2019-04-24 CO CONC2019/0004102A patent/CO2019004102A2/es unknown
- 2019-05-07 EC ECSENADI201931754A patent/ECSP19031754A/es unknown
- 2019-11-26 US US16/696,403 patent/US11305015B2/en active Active
-
2022
- 2022-10-21 JP JP2022169043A patent/JP7478794B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019531745A5 (OSRAM) | ||
| JP2019502371A5 (OSRAM) | ||
| Busselaar et al. | Helpless priming sends CD8+ T cells on the road to exhaustion | |
| Taki et al. | Tumor immune microenvironment during epithelial–mesenchymal transition | |
| US11186822B2 (en) | Genetically-modified immune cells comprising a microRNA-adapted shRNA (shRNAmiR) | |
| Zeng et al. | Exhausted T cells and epigenetic status | |
| Nishimura et al. | Generation of rejuvenated antigen-specific T cells by reprogramming to pluripotency and redifferentiation | |
| JP2019176869A5 (OSRAM) | ||
| Suehiro et al. | Clinical outcomes of a novel therapeutic vaccine with Tax peptide‐pulsed dendritic cells for adult T cell leukaemia/lymphoma in a pilot study | |
| CN104087592B (zh) | Afp158-166特异性tcr基因及其转基因t细胞及体外增殖方法及用途 | |
| Kamphorst et al. | CD4 T-cell immunotherapy for chronic viral infections and cancer | |
| KR102357004B1 (ko) | 입양 세포 면역요법의 효능을 강화하기 위한 조성물 및 방법 | |
| Abdul‐Wahid et al. | Induction of antigen‐specific TH9 immunity accompanied by mast cell activation blocks tumor cell engraftment | |
| CN110036112B (zh) | 引发受主要组织相容性复合体e分子限制的t细胞的巨细胞病毒载体 | |
| Su et al. | Nasopharyngeal carcinoma and its microenvironment: past, current, and future perspectives | |
| JP2018522072A5 (OSRAM) | ||
| Redeker et al. | The quantity of autocrine IL-2 governs the expansion potential of CD8+ T cells | |
| Zhou et al. | Cancer vaccines: current status and future directions | |
| Nishimura et al. | Cancer immunotherapy using novel tumor‐associated antigenic peptides identified by genome‐wide cDNA microarray analyses | |
| JP2017522312A5 (OSRAM) | ||
| Ryan | microRNAs in cancer susceptibility | |
| Sundarasetty et al. | Lentivirus-induced ‘Smart’dendritic cells: Pharmacodynamics and GMP-compliant production for immunotherapy against TRP2-positive melanoma | |
| RU2016139643A (ru) | Способ создания т-клеток, пригодных для аллогенной трансплантации | |
| JP2018520669A5 (OSRAM) | ||
| Mossoba et al. | Cancer immunotherapy using virally transduced dendritic cells: animal studies and human clinical trials |